Late-stage CMC
The program changes as the asset matures. Your CMC strategy has to change with it.
Late-stage development is where independent technical workstreams become one integrated registration and launch system. Drug substance, drug product, analytical methods, specifications, stability, process validation, clinical supply and commercial readiness must converge on the same product and the same timeline.
01
Development strategy
Define the critical CMC questions, decision sequence, evidence package, and work that genuinely gates Phase 3, registration, or launch.
02
Registration readiness
Align process, analytical, stability, comparability, specifications and manufacturing evidence with the filing strategy.
03
Manufacturing network
Build a network that can support clinical demand, registration campaigns, validation, launch inventory and commercial continuity.
Where we add the most value
Programs often engage Ghlobe when:
- Phase 2 data are increasing the probability of a pivotal program.
- A process or formulation must move from development scale to registration scale.
- Technical transfer to a new CDMO is strategically necessary.
- A critical unit operation is not scaling predictably.
- Phase 3 clinical supply and registration manufacturing timelines are colliding.
- A small internal CMC team needs executive-level leadership across multiple external partners.
- The company needs an integrated plan from EOP2 or pivotal development through NDA and launch.
